Suggestions
Max Narovlyansky
Scientist and entrepreneur
Professional Background
Max Narovlyansky is a distinguished professional in the field of medical device design and development, holding extensive expertise in microfluidics and immunodiagnostics. With an impressive track record that spans over two decades, Max demonstrates a profound passion for innovating point-of-care devices that leverage cutting-edge detection methods suitable for enhancing clinical outcomes. His previous roles have seen him contributing significantly to organizations ranging from startups to established healthcare giants, showcasing his versatile skill set and leadership capabilities.
Max's career began as a Graduate Student Researcher at Harvard University, where he demonstrated an early proficiency in biochemistry. This foundation paved the way for his academic advancement, culminating in a Ph.D. in Biochemistry from the prestigious Harvard University. His research endeavors were complemented by a Bachelor of Science in Chemistry from California Institute of Technology (Caltech), further solidifying his scientific acumen.
Throughout his career, Max has held several key positions that highlight his leadership and innovative spirit. As the Chief Executive Officer at Sanus Galt Inc, he steered the company through pivotal growth phases, driving development of medical devices that are not only effective but also cost-efficient. His leadership approach fosters a culture of collaboration and scientific exploration, enabling teams to achieve remarkable outcomes in healthcare technology.
Prior to his tenure at Sanus Galt Inc, Max served as a Senior Scientist at Xheme and was pivotal in spearheading projects that improved product efficacy through the innovative application of microfluidics. As the Founder of FlowCell, he launched a venture focused on developing novel devices designed to enhance clinical diagnostics, a testament to his entrepreneurial spirit and commitment to advancing healthcare.
Max's role as Director of Assay Development at Eutropics Pharmaceuticals allowed him to refine his expertise in regulatory environments and clinical study administration, particularly in the context of FDA 510k submissions—crucial for bringing medical innovations to market.
Additionally, he has excelled as a Principal Scientist at Instrumentation Laboratory and a Senior Research Scientist at Abbott, where he was engaged in the integration of data analysis, algorithm development, and process controls, including the execution of Six Sigma methodologies for optimizing operations. His tenure at Abbott further honed his skills in clinical testing and biochemistry.
Max’s career trajectory also includes notable research positions at Baylor University as a Post-doctoral Researcher, and at Merck as a Staff Biologist, where he cultivated a practical understanding of cross-functional collaboration in the biotech landscape. His foundational experiences as a Research Assistant at the Institute of Chemistry and Chemical Biology also enriched his early research capabilities, establishing a solid base for future innovations.
Education and Achievements
Max Narovlyansky's robust educational background lays the groundwork for his professional journey. He holds a Ph.D. in Biochemistry from Harvard University, a program renowned for its rigorous standards and emphasis on groundbreaking research. During his Ph.D., Max developed specialized knowledge that propelled his expertise in medical devices, particularly in the seamless integration of chemistry and biology.
Additionally, Max earned a Bachelor of Science in Chemistry from the California Institute of Technology (Caltech)—an institution recognized for its commitment to scientific advancement and technological development. His education not only provided him with a strong theoretical foundation but also equipped him with practical skills that are essential in the fast-evolving field of medical technology.
Throughout his career, Max has made significant contributions to the scientific community and has been recognized for his thought leadership in areas such as data analysis, algorithm development, and process optimization. His expertise in cost-effective processes and root cause investigations has made a lasting impact on the evolution of medical devices, reinforcing his reputation as an industry leader.
Achievements
Max Narovlyansky has several noteworthy achievements that highlight his commitment to medical innovation:
- Leadership at Sanus Galt Inc: As CEO, Max successfully led the development of innovative point-of-care devices that harness microfluidics, significantly advancing diagnostic capabilities in clinical settings.
- Pioneering Point-of-Care Devices: His work in microfluidics has paved the way for improved detection methods, making diagnostics faster and more reliable, which is vital in today’s healthcare landscape.
- Regulatory Expertise: Max’s detailed understanding of the regulatory landscape, particularly in FDA submis
Highlights
Without an emergent new source of revenue, the US $34T mountain of debt is insurmountable. Here we describe our plans to address this problem, while making the most of this amazing opportunity for “doing good by doing well”.
On average, hospitals in the US don't make money. Monetization of medical data by hospitals can help them to close the financial gap and provide better, more personalized care to patients. https://lnkd.in/eTU4FG7m #precisionmedicine #biofintech #fintech #hospitals
